Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 3/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL784347 | 0.81 | ADORA1 (0.40) | ADORA2AADORA1 | |
| SCHEMBL12924661 | 0.74 | HCAR3 (0.36) | ADORA2AADORA1 | |
| SCHEMBL12149907 | 0.74 | LMNA (0.30) | — | |
| SCHEMBL784212 | 0.74 | ACHE (0.33) | ADORA2AADORA1 | |
| SCHEMBL12277836 | 0.73 | PNP (0.34) | PNP | |
| SCHEMBL14816701 | 0.73 | PNP (0.36) | PNP | |
| Hydrochloric Acid SCHEMBL15574229 | 0.72 | PNP (0.44) | PNP | |
| SCHEMBL12410909 | 0.70 | ALDH1A1 (0.36) | ADORA2AADORA1 | |
| SCHEMBL12410701 | 0.70 | BRD4 (0.36) | — | |
| SCHEMBL12410700 | 0.70 | NOTUM (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9732110-B2 | Nucleoside and nucleotide derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2017-08-15 | — | — | US | disclosed |
| US-9732110-B2 | Nucleoside and nucleotide derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2017-08-15 | — | — | US | disclosed |
| US-9675632-B2 | Nucleoside and nucleotide derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-9675632-B2 | Nucleoside and nucleotide derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-20160159843-A1 | NUCLEOSIDE AND NUCLEOTIDE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2016-06-09 | — | — | US | disclosed |
| US-20160058783-A1 | NUCLEOSIDE AND NUCLEOTIDE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2016-03-03 | — | — | US | disclosed |
| US-9085599-B2 | 2′allene-substituted nucleoside derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2015-07-21 | — | — | US | disclosed |
| US-8575119-B2 | 2′-chloroacetylenyl substituted nucleoside derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2013-11-05 | — | — | US | disclosed |
| US-20130078217-A1 | 2'-CHLOROACETYLENYL SUBSTITUTED NUCLEOSIDE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2013-03-28 | — | — | US | disclosed |
| US-20120237480-A1 | 2'ALLENE-SUBSTITUTED NUCLEOSIDE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2012-09-20 | — | — | US | disclosed |
| US-8163707-B2 | 4′-allene-substituted nucleoside derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20100074889-A1 | 4'-ALLENE-SUBSTITUTED NUCLEOSIDE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160159843-A1 | NUCLEOSIDE AND NUCLEOTIDE DERIVATIVES | PCNA, ENTPD5, NME2 | PNP 8/4885ADORA2A 214/4885ADORA1 188/4885 |
| US-20120237480-A1 | 2'ALLENE-SUBSTITUTED NUCLEOSIDE DERIVATIVES | NME2, HAVCR2, ENTPD5 | PNP 4/4885ADORA2A 10/4885ADORA1 42/4885 |
| US-20100074889-A1 | 4'-ALLENE-SUBSTITUTED NUCLEOSIDE DERIVATIVES | CCNI, CCNA1, CDK1 | PNP 17/4885ADORA2A 196/4885ADORA1 144/4885 |
| US-20130078217-A1 | 2'-CHLOROACETYLENYL SUBSTITUTED NUCLEOSIDE DERIVATIVES | DUT, HAVCR2, HCCS | PNP 7/4885ADORA2A 180/4885ADORA1 272/4885 |
| US-20160058783-A1 | NUCLEOSIDE AND NUCLEOTIDE DERIVATIVES | PCNA, ENTPD5, NME2 | PNP 8/4885ADORA2A 214/4885ADORA1 188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.